No Data
No Data
Express News | B of A Securities Reinstates Underperform on Bausch & Lomb, Announces $18 Price Target
BofA Securities Downgrades Bausch + Lomb Corp.(BLCO.US) to Sell Rating
Bausch & Lomb Edges Higher After Confirming Sales Process
Bausch Health Says Board Authorized Management To Explore Potential Sale Of Subsidiary Bausch + Lomb; Says Process Is Ongoing. No Decision Has Been Reached
Bausch + Lomb Responds to Rumors of a Potential Sale
H.C. Wainwright Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $23
No Data
Benjamin’s : New CEO